scholarly journals Menopause Induced Depression, Anxiety, Quality of Life, Lack of Sleep in Women: An Overview

2021 ◽  
Vol 11 (6) ◽  
pp. 319-323
Author(s):  
Arivazhagan Ragasudha ◽  
Skaria Minnu ◽  
R Sambath Kumar
Keyword(s):  
Quality Of Life ◽  
Menstrual Cycle ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Age Related ◽  
Lack Of Sleep ◽  
Post Menopause

Background: Menopause occurs between the ages of 40 and 50, and marks the end of a woman's menstrual cycle. A period of time during which a woman does not have a monthly cycle for more than 12 months is known as post-menopause. Women may suffer challenges in their daily lives during this period, such as depression, anxiety, and sleep loss, all of which can have a negative impact on their quality of life. A decrease in hormone production, such as estrogen and progesterone, can cause menopause. To treat psychological difficulties in menopausal women, drugs such as vortioxetine and paroxetine, as well as selective serotonin reuptake inhibitors (SSRI) and anti-depressants, were advised. Objective: To evaluate the effects in women how menopause inducing depression, anxiety, quality of life and lack of sleep. Methodology: The recent studies related to the aim of the review were undertaken through a literature search to evaluate the effects in women how menopause inducing depression, anxiety, quality of life and lack of sleep. Conclusion: Menopause, post-menopause, and peri-menopause are age-related causes in women who are going through the menstrual cycle. There is no need for medication during this time, but in severe cases, medications such as selective serotonin reuptake inhibitors (SSRI) and antidepressants should be administered and also for vaginal dryness and irritation Ospemifene is suggested. Many more clinical researches on the benefits of menopausal compilations will be needed in the future. Keywords: Menopause, post- menopause, depression, estrogen, progesterone

Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life

1998 ◽  
Vol 12 (4_suppl) ◽  
pp. S21-S54 ◽  
Author(s):  
Paul J. Goodnick ◽  
Burton J. Goldstein
Keyword(s):  
Quality Of Life ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Quality Of Data ◽  
Affective Symptoms ◽  
Wide Range ◽  
Favorable Side Effect Profile

Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.

scholarly journals PEMANFAATAN ANTIDEPRESAN PADA DEPRESI LANJUT USIA

2020 ◽  
Vol 11 (2) ◽  
Author(s):  
Sang Ayu Arta Suryantari ◽  
Agung Bagus Sista Satyarsa
Keyword(s):  
Quality Of Life ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Old People

Depresi pada lanjut usia (lansia) adalah penyakit yang berhubungan dengan disabilitas dengan penurunan fungsional dan kognitif yang sangat mempengaruhi kualitas hidup. Studi yang mempelajari pengobatan antidepresan pada lansia masih minimal dan menunjukan efek yang sering berlawanan. Tujuan dari literatur ini adalah untuk mendiskripsikan pemanfaatan antidepresan pada depresi lanjut usia. Metode yang digunakan adalah dengan mencari artikel valid dibasis data PubMed dan Medline dari dalam sepuluh tahun terakhir. Pencarian menggunakan kata kunci yakni “Antidepressants” and “Old people” and “Depression” and “Quality of Life”. Berdasarkan hasil pencarian didapatkan total 27 artikel yang sesuai dengan kriteria tersebut. Selective serotonin reuptake inhibitors (SSRIs) dan antidepresan generasi kedua lainnya direkomendasikan untuk pengobatan lini pertama depresi pada lansia. Perbedaan efikasi dan tolerabilitas dalam berbagai substansi dan golongan obat minimal atau tidak ada. Pada depresi yang resisten terhadap pengobatan, terapi augmentasi dipilih seperti litium dan antipsikotik atipikal. Diperlukan adanya bukti yang meyakinkan bahwa antidepresan bermanfaat dalam pengobatan depresi pada lanjut usia yang rasional. Namun, data berbasis bukti pada tingkat pemulihan dan remisi pada depresi lanjut usia terhadap obat antidepresan tertentu masih dalam uji coba dan data ini sangat penting untuk pengobatan farmakologis depresi lanjut usia dalam praktik klinis sehari-hari.

Efficacy of Traditional Chinese Medicine Combined with Selective Serotonin Reuptake Inhibitors on the Treatment for Parkinson’s Disease with Depression: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 49 (03) ◽  
pp. 627-643
Author(s):  
Si-Tong Feng ◽  
Xiao-Le Wang ◽  
Ya-Ting Wang ◽  
Yu-He Yuan ◽  
Zhi-Peng Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin

Depression is a common neuropsychiatric symptom of Parkinson’s disease (PD), resulting in a lower quality of life and cognitive impairment in PD patients. Traditional Chinese medicine (TCM) formulas have been widely used in neurodegenerative disease and neuropsychic disorders to improve life quality of patients in ethnomedicine. TCM formulas combined with selective serotonin reuptake inhibitors (SSRIs) also have a positive effect on depressed PD compared with SSRIs as reported by several clinical studies. However, the results are discordant and failed to be conclusive. We aim to evaluate the efficacy of TCM formulas combined with SSRIs for depressed PD in this systematic review. We searched literatures from PubMed, Web of Science, Medline, Embase, Google Scholar, Chinese National Knowledge Infrastructure, Wanfang Database, and VIP Information Database before July 2020. We included randomized controlled trials investigating the efficacy of TCM formulas combined with SSRIs on depressed PD patients. This analysis was according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Eleven randomized clinical trials involving 861 subjects were enrolled in this analysis. The overall results showed that TCM formulas combined with SSRIs significantly improved the depression score [weighted mean difference (WMD): −4.920, 95% confidence interval (CI): (−5.999, −3.840); [Formula: see text]¡ 0.001] and had a statistical significance on Unified Parkinson’s Disease Rating Scale II score [WMD: −1.209, 95% CI: (−1.561, −0.857); [Formula: see text] < 0.001]. Furthermore, we observed that Chai-Hu-Shu-Gan Powder combined with SSRIs had a significant improvement on the depressive symptom in PD compared to the SSRIs alone [WMD: −5.390, 95% CI: (−7.66, −3.11); [Formula: see text] < 0.001]. No severe side events were reported in these included trials. This systematic review provided the evidences that TCM formulas combined with SSRIs might be helpful and safe in the treatment of depression of PD, including Chai-Hu-Shu-Gan Powder. Also, more randomized double-blinded trials with reliable design are required in the future.

Novel Uses of Selective Serotonin Reuptake Inhibitors in Women

2003 ◽  
Vol 16 (3) ◽  
pp. 191-199
Author(s):  
Shareen Y. El-Ibiary ◽  
Kelly C. Lee
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Hot Flashes ◽  
Premenstrual Dysphoric Disorder ◽  
Physical Symptoms ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
First Line Therapy ◽  
Current Therapies

Selective serotonin reuptake inhibitors (SSRIs) are commonly used as first-line therapy to treat mood disorders due to their demonstrated efficacy, safety, and tolerability profiles. SSRIs may play an intricate role in treating hormone-mediated disorders that disturb the quality of life for women. Selected uses of SSRIs, specifically in the treatment of hot flashes, premenstrual dysphoric disorder, and postpartum depression, are explored in this article. Data from several studies support the use of SSRIs in these conditions, and therefore, these agents have the potential to significantly improve mood, cognitive function, physical symptoms, and social functioning in patients with these disorders. In addition, SSRIs may prove to be viable alternatives to current therapies that may be contraindicated, poorly tolerated, or lack efficacy in patients with these disorders.

Sign in / Sign up

Export Citation Format

Share Document